Browsing: Volume 2 Issue 4 – April 2026
Longevity and Mortality Investor’s Editor’s Letter for the April 2026 issue.
Two recent litigation cases produced opposite results for the life settlement market.
Industry continues to model the potential upside of a successful rollout of MCED technology despite its newness.
Highest ever volume of buy-in transactions show market in maturation stage.
How durational mortality curves, stochastic A/E analysis and independent audits can strengthen investor confidence and fund sustainability.
Why a different approach might be needed to bring the UK’s secondary life insurance market back to life.
Efforts to find treatments that slow or prevent Alzheimer’s disease are making good progress, but the complexities of tackling the illness…
LifeRoc Capital’s Brandon Marz provides his thoughts on the state of the life settlement industry’s secondary market in this month’s Q&A.
Latest CMI model not likely to have material impact on pensions de-risking activity.
The European Insurance and Occupational Pensions Authority (EIOPA) has turned its head towards the almost zeitgeist topic of ‘private equity’ ownership of life insurers.…